Markets

Opioid addiction crisis: the cost of killing pain

Given the economic burden of opioid addiction in the US and the political attention it receives, we believe there will be opportunities for companies offering solutions, as well as risks to those companies implicated in its causes.

17/01/2018

Seema Suchak

Seema Suchak

Sustainable Investment Analyst

A national opioid crisis has hit the US, with addiction numbers increasing fivefold over the past seven years. In 2015, more than one in three Americans was prescribed opioids to treat pain.

Now, major opioid drug manufacturers have been sued by over 30 states, cities or counties in the US. The drug companies are alleged to have underplayed the addictive qualities of the drugs and overstated their benefits.

The cost of addiction paints a bleak picture. The total economic burden of prescription opioid and heroin abuse in the US has been estimated at $78.5 billion annually, nearly 25% of which is shouldered by public sources (via drug rehabilitation, foster care, Medicaid costs, etc).

Federal Reserve Chair Janet Yellen recently said the crisis has weighed on labour force participation, particularly among working-age men, and Donald Trump has declared it a “public health emergency”. These factors have built a heavy case for heightened scrutiny and legislative action.

While media and market attention focuses on the drug companies caught up in the legal proceedings, we believe the implications spread further. We have mapped risks and opportunities across sectors, tracked corporate responses, and spoken with companies.

Given the burden of opioid addiction on the US economy and the political attention it receives, we believe there will be opportunities for companies offering solutions as well as risks to those companies implicated in its causes.

Rapid escalation

Opioids are a class of drug that includes heroin, synthetic opioids such as fentanyl, and pain relievers available legally by prescription in the US, such as oxycodone, hydrocodone, and many others. Access to legal category medications has been reduced given the problems caused by their overuse, but the problem has now spilled over into abuse of stronger and illegal opioids such as heroin.

While the number of deaths from the overdose of prescribed opioids has flattened over the past few years, the number of heroin-related deaths has soared, with over 70% of heroin addiction originating from prescribed painkiller abuse.

Several actions are being taken to address the challenge, including a series of civil lawsuits (30 and rising) against five major opioid manufacturers, and a Senate Committee investigation into 10 manufacturers, three distributors and three Pharmacy Benefit Managers. The US Drug Enforcement Administration (DEA) has also lowered its manufacturing quotas for opioids in an attempt to restrict unnecessary consumption.

Beyond drugmakers

Opioid manufacturers are already in the cross-hairs, and those companies reliant on opioids for their revenues are seeing the effects. But the issue extends more broadly, as indicated in the table below. 

The new tobacco?

Parallels have been drawn between the opioid epidemic and the Big Tobacco settlements of the 1990s. In reality, there are some stark differences, not least the system by which these drugs have been prescribed, sold, distributed and insured. For example, insurance plans may have covered prescription opioids, but not other painkillers which are more expensive but less addictive. Physicians have been criticised for prescribing painkillers rather than tackling the root cause of pain.

This partly explains the varied corporate response to the crisis, with some companies tackling the issue head on and amending corporate practices, others rushing to innovate the next generation of painkiller, and still others denying their involvement or attempting to defer the blame to those that prescribe the drug. Our work to determine the strength of corporate responses is helping us navigate the investment implications of this health crisis.

 

 

Important information

This communication is marketing material. The views and opinions contained herein are those of the named author(s) on this page, and may not necessarily represent views expressed or reflected in other Schroders communications, strategies or funds.

This document is intended to be for information purposes only and it is not intended as promotional material in any respect. The material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The material is not intended to provide, and should not be relied on for, accounting, legal or tax advice, or investment recommendations. Information herein is believed to be reliable but Schroder Investment Management Ltd (Schroders) does not warrant its completeness or accuracy.

The data has been sourced by Schroders and should be independently verified before further publication or use. No responsibility can be accepted for error of fact or opinion. This does not exclude or restrict any duty or liability that Schroders has to its customers under the Financial Services and Markets Act 2000 (as amended from time to time) or any other regulatory system. Reliance should not be placed on the views and information in the document when taking individual investment and/or strategic decisions.

Past Performance is not a guide to future performance. The value of investments and the income from them may go down as well as up and investors may not get back the amounts originally invested.  Exchange rate changes may cause the value of any overseas investments to rise or fall.

Any sectors, securities, regions or countries shown above are for illustrative purposes only and are not to be considered a recommendation to buy or sell.

The forecasts included should not be relied upon, are not guaranteed and are provided only as at the date of issue. Our forecasts are based on our own assumptions which may change. Forecasts and assumptions may be affected by external economic or other factors.

Issued by Schroder Unit Trusts Limited, 1 London Wall Place, London EC2Y 5AU. Registered Number 4191730 England. Authorised and regulated by the Financial Conduct Authority.